REPLIGEN CORP (RGEN) Fundamental Analysis & Valuation

NASDAQ:RGEN • US7599161095

Current stock price

128.92 USD
+6.33 (+5.16%)
Last:

This RGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. RGEN Profitability Analysis

1.1 Basic Checks

  • In the past year RGEN was profitable.
  • RGEN had a positive operating cash flow in the past year.
  • RGEN had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years RGEN had a positive operating cash flow.
RGEN Yearly Net Income VS EBIT VS OCF VS FCFRGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

1.2 Ratios

  • RGEN's Return On Assets of 1.66% is fine compared to the rest of the industry. RGEN outperforms 68.42% of its industry peers.
  • RGEN has a better Return On Equity (2.32%) than 70.18% of its industry peers.
  • RGEN's Return On Invested Capital of 1.65% is fine compared to the rest of the industry. RGEN outperforms 61.40% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 11.38%.
  • The last Return On Invested Capital (1.65%) for RGEN is above the 3 year average (1.45%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.66%
ROE 2.32%
ROIC 1.65%
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.45%
ROIC(5y)3.72%
RGEN Yearly ROA, ROE, ROICRGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 4 6 8

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.62%, RGEN is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
  • RGEN's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 8.03%, RGEN is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • RGEN's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 52.65%, RGEN is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • RGEN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.03%
PM (TTM) 6.62%
GM 52.65%
OM growth 3Y-31%
OM growth 5Y-16.8%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.53%
GM growth 5Y-1.65%
RGEN Yearly Profit, Operating, Gross MarginsRGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RGEN Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGEN is destroying value.
  • The number of shares outstanding for RGEN has been increased compared to 1 year ago.
  • Compared to 5 years ago, RGEN has more shares outstanding
  • RGEN has a better debt/assets ratio than last year.
RGEN Yearly Shares OutstandingRGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
RGEN Yearly Total Debt VS Total AssetsRGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 5.86 indicates that RGEN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of RGEN (5.86) is better than 85.96% of its industry peers.
  • RGEN has a debt to FCF ratio of 5.91. This is a neutral value as RGEN would need 5.91 years to pay back of all of its debts.
  • The Debt to FCF ratio of RGEN (5.91) is better than 70.18% of its industry peers.
  • RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
  • RGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.91
Altman-Z 5.86
ROIC/WACC0.15
WACC10.68%
RGEN Yearly LT Debt VS Equity VS FCFRGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • RGEN has a Current Ratio of 8.37. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 8.37, RGEN belongs to the best of the industry, outperforming 94.74% of the companies in the same industry.
  • A Quick Ratio of 7.12 indicates that RGEN has no problem at all paying its short term obligations.
  • The Quick ratio of RGEN (7.12) is better than 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 8.37
Quick Ratio 7.12
RGEN Yearly Current Assets VS Current LiabilitesRGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.54% over the past year.
  • RGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.60% yearly.
  • Looking at the last year, RGEN shows a decrease in Revenue. The Revenue has decreased by -6.05% in the last year.
  • Measured over the past years, RGEN shows a quite strong growth in Revenue. The Revenue has been growing by 15.05% on average per year.
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.07% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.56% on average per year.
EPS Next Y17.13%
EPS Next 2Y21.88%
EPS Next 3Y23.65%
EPS Next 5Y26.07%
Revenue Next Year12.85%
Revenue Next 2Y13.68%
Revenue Next 3Y14.21%
Revenue Next 5Y15.56%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
RGEN Yearly Revenue VS EstimatesRGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
RGEN Yearly EPS VS EstimatesRGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

2

4. RGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • RGEN is valuated quite expensively with a Price/Earnings ratio of 75.39.
  • Compared to the rest of the industry, the Price/Earnings ratio of RGEN is on the same level as its industry peers.
  • When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (27.18), we can say RGEN is valued expensively.
  • RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 64.37.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of RGEN is on the same level as its industry peers.
  • RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 37.96, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 75.39
Fwd PE 64.37
RGEN Price Earnings VS Forward Price EarningsRGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RGEN is on the same level as its industry peers.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
Industry RankSector Rank
P/FCF 79.3
EV/EBITDA 46.99
RGEN Per share dataRGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
  • RGEN has a very decent profitability rating, which may justify a higher PE ratio.
  • RGEN's earnings are expected to grow with 23.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.4
PEG (5Y)126.65
EPS Next 2Y21.88%
EPS Next 3Y23.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RGEN Dividend Analysis

5.1 Amount

  • No dividends for RGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RGEN Fundamentals: All Metrics, Ratios and Statistics

REPLIGEN CORP

NASDAQ:RGEN (4/14/2026, 1:14:36 PM)

128.92

+6.33 (+5.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners112.24%
Inst Owner Change0%
Ins Owners0.32%
Ins Owner Change-3.37%
Market Cap7.27B
Revenue(TTM)738.26M
Net Income(TTM)48.89M
Analysts81.43
Price Target191.89 (48.84%)
Short Float %10.46%
Short Ratio6.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.52%
Min EPS beat(2)7.78%
Max EPS beat(2)9.25%
EPS beat(4)3
Avg EPS beat(4)5.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)5
Avg EPS beat(8)5.28%
EPS beat(12)8
Avg EPS beat(12)7.82%
EPS beat(16)12
Avg EPS beat(16)10.63%
Revenue beat(2)2
Avg Revenue beat(2)1.33%
Min Revenue beat(2)0.58%
Max Revenue beat(2)2.07%
Revenue beat(4)4
Avg Revenue beat(4)1.51%
Min Revenue beat(4)0.58%
Max Revenue beat(4)2.15%
Revenue beat(8)4
Avg Revenue beat(8)-0.01%
Revenue beat(12)4
Avg Revenue beat(12)-0.88%
Revenue beat(16)7
Avg Revenue beat(16)0.5%
PT rev (1m)0.19%
PT rev (3m)-0.61%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)-13.63%
EPS NY rev (1m)0.58%
EPS NY rev (3m)-4.92%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)0.49%
Revenue NY rev (1m)0.16%
Revenue NY rev (3m)0.38%
Valuation
Industry RankSector Rank
PE 75.39
Fwd PE 64.37
P/S 9.85
P/FCF 79.3
P/OCF 61.93
P/B 3.45
P/tB 12.01
EV/EBITDA 46.99
EPS(TTM)1.71
EY1.33%
EPS(NY)2
Fwd EY1.55%
FCF(TTM)1.63
FCFY1.26%
OCF(TTM)2.08
OCFY1.61%
SpS13.09
BVpS37.34
TBVpS10.74
PEG (NY)4.4
PEG (5Y)126.65
Graham Number37.9
Profitability
Industry RankSector Rank
ROA 1.66%
ROE 2.32%
ROCE 2.11%
ROIC 1.65%
ROICexc 2.27%
ROICexgc 8.52%
OM 8.03%
PM (TTM) 6.62%
GM 52.65%
FCFM 12.42%
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.45%
ROIC(5y)3.72%
ROICexc(3y)2.01%
ROICexc(5y)5.28%
ROICexgc(3y)7.46%
ROICexgc(5y)30.51%
ROCE(3y)1.85%
ROCE(5y)4.75%
ROICexgc growth 3Y-45.78%
ROICexgc growth 5YN/A
ROICexc growth 3Y-39.51%
ROICexc growth 5Y-19.39%
OM growth 3Y-31%
OM growth 5Y-16.8%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.53%
GM growth 5Y-1.65%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.91
Debt/EBITDA 3.93
Cap/Depr 32.68%
Cap/Sales 3.49%
Interest Coverage 250
Cash Conversion 85.06%
Profit Quality 187.52%
Current Ratio 8.37
Quick Ratio 7.12
Altman-Z 5.86
F-Score6
WACC10.68%
ROIC/WACC0.15
Cap/Depr(3y)44.28%
Cap/Depr(5y)98.33%
Cap/Sales(3y)4.79%
Cap/Sales(5y)7.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
EPS Next Y17.13%
EPS Next 2Y21.88%
EPS Next 3Y23.65%
EPS Next 5Y26.07%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%
Revenue Next Year12.85%
Revenue Next 2Y13.68%
Revenue Next 3Y14.21%
Revenue Next 5Y15.56%
EBIT growth 1Y282.37%
EBIT growth 3Y-32.87%
EBIT growth 5Y-4.28%
EBIT Next Year81.31%
EBIT Next 3Y42.03%
EBIT Next 5Y37.01%
FCF growth 1Y-36.98%
FCF growth 3Y3.04%
FCF growth 5Y20.36%
OCF growth 1Y-33.06%
OCF growth 3Y-11.97%
OCF growth 5Y13.4%

REPLIGEN CORP / RGEN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for REPLIGEN CORP?

ChartMill assigns a fundamental rating of 5 / 10 to RGEN.


What is the valuation status for RGEN stock?

ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.


How profitable is REPLIGEN CORP (RGEN) stock?

REPLIGEN CORP (RGEN) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for RGEN stock?

The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 75.39 and the Price/Book (PB) ratio is 3.45.


What is the earnings growth outlook for REPLIGEN CORP?

The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 17.13% in the next year.